NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

膽管癌症治療的全球市場:2020年∼2027年

Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - 2020-2027

出版商 DataM Intelligence 商品編碼 1004985
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
膽管癌症治療的全球市場:2020年∼2027年 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - 2020-2027
出版日期: 2021年05月12日內容資訊: 英文 180 Pages
簡介

由於全球的膽管癌症的盛行率增加,老年人增加,生活方式的變化,抽煙習慣增加,研究開發活動的投資增加等,成為全球膽管癌症治療市場成長的主要原因。

本報告提供全球膽管癌症治療市場相關調查分析,產業分析,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 全球膽管癌症治療市場調查手法與調查範圍

第2章 全球膽管癌症治療市場:市場定義與市場概要

第3章 全球膽管癌症治療市場:摘要整理

第4章 全球膽管癌症治療市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球膽管癌症治療市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球膽管癌症治療市場:COVID-19分析

  • 對市場的COVID-19分析
  • 在COVID-19中的價格趨勢
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球膽管癌症治療市場:癌症的各類型

  • 簡介
  • 癌症的各種類市場區隔的市場規模分析、與前一年同期比較成長率分析
  • 癌症的各種類市場區隔的市場魅力指數
    • 肝外膽管癌症
    • 其他

第8章 全球膽管癌症治療市場:各治療類型

  • 簡介
  • 各治療類型的市場規模分析、與前一年同期比較成長率分析
  • 各治療類型的市場魅力指數
    • 化療
    • 光線動態療法
    • 手術
    • 放射線治療
    • 其他

第9章 全球膽管癌症治療市場:各終端用戶

  • 簡介
  • 各終端用戶市場區隔的市場規模分析、與前一年同期比較成長率分析
  • 各終端用戶市場區隔的市場魅力指數
    • 醫院
    • 診所
    • 癌症研究機關
    • 其他

第10章 全球膽管癌症治療市場:各地區

  • 簡介
  • 各地區的市場規模分析、與前一年同期比較成長率分析
  • 各地區的市場魅力指數
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東、非洲

第11章 全球膽管癌症治療市場:競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第12章 全球膽管癌症治療市場:企業簡介

  • Hoffmann-La Roche Ltd
  • ConMed Corporation
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Novartis AG
  • Sanofi
  • Incyte Corporation
  • Celgene Corporation
  • Bayer AG
  • Boston Scientific Corporation等

第13章 全球膽管癌症治療市場:重要考察

第14章 全球膽管癌症治療市場:DataM

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Bile Duct Cancer, also known as Cholangiocarcinoma, forms in the slender tubes (bile ducts) that carry the digestive fluid bile. Bile ducts connect the liver to the gallbladder and small intestine. It occurs mainly in people older than age 50, though it can occur at any age. The particular causes of bile duct cancer are unknown. However, few factors responsible for developing bile duct cancer are long-term inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection with liver fluke's parasite that causes mainly infection in the bile duct leading to cancer, and exposure to harmful chemicals and toxins. Major symptoms associated with bile duct cancer include jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching, and fever. Bile duct cancer is treated by Chemotherapy, Surgery, Radiation therapy, Targeted therapy and Others.

Market Dynamics

The global Bile Duct Cancer (Cholangiocarcinoma) Treatment growth is driven by the increasing prevalence of bile duct cancers worldwide, increasing geriatric population, changing lifestyle and increasing smoking habits; rising investment in research and development activities are the major factors driving the market.

The increasing prevalence of bile duct cancers worldwide is expected to drive the growth in the forecast period.

Bile duct cancer (Cholangiocarcinoma) is rare. As per the National Cancer Institute, the rate of new cases of bile duct cancer was 9.0 per 100,000 men and women per year. In 2018, an estimated 96,178 people were living with bile duct cancer in the United States. In 2021, it is estimated that there will be 42,230 new cases of bile duct cancer are estimated. This includes intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers, but the actual number of cases is likely to be higher because these cancers can be hard to diagnose, and some might be misclassified as other types of cancer. These factors are majorly driving the growth of the market.

High treatment costs are likely to hinder market growth.

According to the American cancer clinical society, approximate bile duct Cancer Treatment cost in India ranges between USD 1500 to USD 15,000. It is a burden for underdeveloped and developing countries. This is one of the factors hampering the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and on the vulvar Cancer market. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.

Segment Analysis

Based on the Cancer Type, the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented into Intrahepatic bile duct cancer and Extrahepatic bile duct cancer.

Intrahepatic bile duct cancer

Intrahepatic bile duct cancer occurs in the bile ducts within the liver and is sometimes classified as a type of liver cancer. This type makes up 5% to 10% of cases.

Extrahepatic bile duct cancer: This type occurs more often and is more treatable might form in one of two areas.

The hilum region, where your left and right bile ducts come together to form the common hepatic duct. It is called perihilar cancer. More than 60% of the plethora of bile duct cancers fall in the category of perihilar bile duct cancers.

The distal Region, where your common bile duct passes through the pancreas. This is called distal cancer.

Based on the Treatment Type, the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented into Chemotherapy, Surgery, Radiation therapy, Photodynamic therapy, and Others.

The chemotherapy segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

Chemotherapy (chemo) is treatment with cancer-killing drugs usually given into a vein (IV) or taken by mouth. These drugs enter the bloodstream and reach all areas of the body, making this helpful treatment for some cancers that have spread to organs beyond the bile duct. As the drugs reach all the areas of the body, this is known as a systemic treatment. The drugs used in chemo are 5-fluorouracil, gemcitabine, capecitabine, oxaliplatin, cisplatin, and combined drug treatment. Factors such as the availability of a wide range of chemotherapeutics agents for the treatment of bile duct cancer and ongoing innovative research work on the improvement of chemotherapy by studying new drugs and new combination of drugs through clinical trials are anticipated to boost the market growth of the chemotherapy segment during the forecast period.

For instance, Incyte Corporation- A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma.

Based on End-User, the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented into Hospitals, Cancer Research centers, clinics, others.

Due to the growing patient population, the hospital segment held the largest market share. This is mainly due to the increasing number of patients suffering from conditions treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals and adequate reimbursement policies are also contributing to the growth of this segment. Also, the medications can be administrated intravenously, and surgery is done under the supervision of medical practitioners at these locations.

Geographical Analysis

Bile Duct Cancer, also known as Cholangiocarcinoma, is spreading widely in Southeast Asia. The high consumption of raw fish in the Asia-Pacific (APAC) region drives the incidence of liver fluke infections, thereby stimulating bile duct cancer. Increased industrialization is also attributing to the growth in the APAC region as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India. For instance, Eisai Co., Ltd- A Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion.

North America holds the second-largest market in the global bile duct cancer market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and photodynamic therapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.

Competitive Landscape

The Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market is quite competitive with some key competitors like ConMed Corporation, Bristol-Myers Squibb, Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Incyte Corporation, Celgene Corp, Bayer AG, and Boston Scientific Corporation. The major players adopt several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, Incyte Corporation-A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma.

Hoffmann-La Roche Ltd

Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to drive personalized healthcare further. Two-thirds of our Research and Development projects are being developed with companion diagnostics. Genentech becomes a member of the Roche Group in March of 2009.

Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases and others.

Key developments:

Diagnostic Test: FoundationOne®CDx and FoundationOne®Liquid are under trials.

Why Purchase the Report?

  • Visualize the composition of the Bile Duct Cancer (Cholangiocarcinoma) Treatment Market segmentation by Cancer type, Treatment type, End-users, and Region, highlighting the key commercial assets and players.
  • Identify commercial opportunities in Bile Duct Cancer (Cholangiocarcinoma) Treatment Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market report would provide access to an approx. 61 market data table, 55 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - Market Definition and Overview

3. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market- Executive Summary

  • 3.1. Market Snippet by Cancer Type
  • 3.2. Market snippet by Treatment Type
  • 3.3. Market Snippet by End-users
  • 3.4. Market Snippet by Region

4. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of Bile Duct Cancers worldwide
    • 4.1.2. Restraints:
      • 4.1.2.1. High Cost of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - By Cancer Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer type Segment
  • 7.3. Market Attractiveness Index, By Cancer type Segment
      • 7.3.1.1. Intrahepatic bile duct cancer*
      • 7.3.1.2. Introduction
      • 7.3.1.3. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Extrahepatic bile duct cancer
    • 7.3.3. Others

8. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - By Treatment type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
  • 8.3. Market Attractiveness Index, By Treatment type
    • 8.3.1. Chemotherapy*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Photodynamic therapy
    • 8.3.3. Surgery
    • 8.3.4. Radiation therapy
    • 8.3.5. Others

9. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - By End-users

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users segment
  • 9.3. Market Attractiveness Index, By End-users Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics
    • 9.3.3. Cancer research institutes
    • 9.3.4. Others

10. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users

11. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - Company Profiles

  • 12.1. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. ConMed Corporation,
  • 12.3. Bristol-Myers Squibb,
  • 12.4. Johnson & Johnson,
  • 12.5. Novartis AG,
  • 12.6. Sanofi,
  • 12.7. Incyte Corporation,
  • 12.8. Celgene Corporation,
  • 12.9. Bayer AG,
  • 12.10. Boston Scientific Corporation

LIST NOT EXHAUSTIVE

13. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - Premium Insights

14. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us